Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. This review summarizes the current literature and tries to define the status of nuclear medicine in the clinical workup of lung cancer patients. Nuclear medicine procedures and positron emission tomography (PET) with the EMEA-approved radiopharmaceutical fluorodeo-xyglucose (FDG) are indicated for the characterization of lung lesions the nodal staging of non-small cell lung cancer (NSCLC)